Examples of using Clostridium difficile in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Clostridium difficile associated diarrhoea.
Uncommon: Positive Clostridium difficile toxin.
Clostridium difficile can cause annoying diarrhea and fever.
Faecal transplant in recurrent Clostridium difficile infection.
Like Clostridium difficile infections that can stay with people for years and years and years.
Pseudomembranous colitis, triggered by Clostridium difficile;
Clostridium difficile associated diarrhoea(CDAD) has been reported for tedizolid phosphate see section 4.8.
Inflammation of the small intestine andthe colon caused by clostridium difficile.
Toxigenic Clostridium difficile is an important cause of diarrhea that occurs more often in the elderly.
An allergic reaction or a type of diarrhea caused by Clostridium difficile is possible.
Auto-catalytic Cleavage of Clostridium difficile Toxins A and B Depends on Cysteine Protease Activity.
Discontinuation of therapy with INVANZ and the administration of specific treatment for Clostridium difficile should be considered.
DIFICLIR is indicated in adults for the treatment of Clostridium difficile infections(CDI) also known as C. difficile-associated diarrhoea(CDAD) see section 5.1.
The authors conducted an analysis of protein deficits in patients hospitalized for diarrhea associated with Clostridium difficile.
The most common organisms are Campylobacter, Clostridium difficile, Clostridium perfringens, and Salmonella.
DIFICLIR is used in adults to treat infections of the lining of the colon(large intestine)with certain bacteria called Clostridium difficile.
Other types of bacteria include Salmonella,Campylobacter and Clostridium Difficile- C-diff linked with antibiotics.
Treatment with acid-reducing medicinal products leads to a slightly increased risk of gastrointestinal infections such as Salmonella,Campylobacter, or Clostridium difficile.
The presence of asymptomatic pathogen bacteria like Clostridium difficile and Escherichia coli.
In the next article the author discussed the modern therapy of another infective threat that affects quite a high percentage of patients of different medical specialties- Clostridium difficile.
Most strains of Pseudomonas aeruginosa, Campylobacter, Acinetobacter, Serratia,Proteus vulgaris, Clostridium difficile, and Leesella are not sensitive to this product.
Treatment with PPIs may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients,also possibly Clostridium difficile.
Severe hepatotoxicity, cardiac toxicity including QTc interval prolongation,severe skin reactions, Clostridium difficile associated colitis, tendon and muscular toxicity(including rhabdomyolysis) are important identified risks of the treatment with moxifloxacin which are already described in the product information(PI) and under close monitoring.
Acid-suppressing medication appears to increase the risk of significant infection after exposure to a number of organisms, including Clostridium difficile, Salmonella, and Campylobacter species.
In such circumstance, the discontinuation of therapy with ceftaroline fosamil andthe use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered.